Xalkori
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the European Commission has approved XALKORI® (crizotinib…
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced final overall survival (OS) data from the PROFILE 1014 trial…
: The major challenge in modern drug discovery has been the design and development of new anticancer drugs with improved efficacy…
The FDA has announced its approval of crizotinib (Xalkori) for the treatment of patients with non–small-cell lung and ROS1…
The number of new cases of ALK-fusion NSCLC is about 9,000 per year in the U.S. and about 45,000 worldwide. Lung cancer is the…
U.S. researchers have uncovered a plethora of mechanisms in ALK-rearranged lung cancers that could drive resistance to Pfizer's…
Herceptin was the poster child of personalized medicine that brought forward the notion that contemporaneously developed…
957 Medical University, in Tochigi-ken, Japan, linked a small subset of NSCLC cases to the EML4–ALK translocation in 2006. Soon…